A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
Epistemonikos ID: c444db5d0dc798fcb68bb8cf707e2f5a2ae237cc
First added on: May 14, 2024